IP Library Granted Patent US 10,308,924
Granted Patent B2
US 10,308,924 · App. 15/919,814 · Granted Jun 4, 2019

Nucleic acid molecules encoding autoactivating type I pancreatic proelastase proteins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,308,924
App. No.
15/919,814
Granted
Jun 4, 2019
Kind
B2
Abstract

The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention.

Claims (34)

1. A nucleic acid molecule encoding an autoactivating type I pancreatic proelastase protein, wherein the autoactivating type I pancreatic proelastase protein comprises an amino acid sequence which is at least 90% identical to a reference amino acid sequence consisting of SEQ ID NO:73 linked at its C-terminus to the N-terminus of SEQ ID NO:1, wherein the first thirteen amino acids of the reference amino acid sequence are P10-P9-P8-P7-P6-P5-P4-P3-P2-P1-P1′-P2′-P3′; and wherein

(a) the amino acid residues at the P10-P5 and P1′-P3′ positions are each independently selected from any natural amino acid;

(b) the amino acid residue at the P4 position is any natural amino acid except glycine, lysine, phenylalanine, tyrosine, tryptophan, or arginine;

(c) the amino acid residue at the P3 position is any natural amino acid except proline or glycine;

(d) the amino acid residue at the P2 position is proline, alanine, leucine, isoleucine, glycine, valine, histidine, or threonine; and

(e) the amino acid residue at the P1 position is alanine, leucine, valine, isoleucine, or serine.

2. The nucleic acid molecule of claim 1 , wherein:

(a) the amino acid residue at the P5 position is glutamate, histidine, proline, glycine, asparagine, lysine, or alanine;

(b) the amino acid residue at the P4 position is threonine, alanine, proline, or histidine;

(c) the amino acid residue at the P3 position is alanine, leucine, isoleucine, methionine, lysine, asparagine, or valine;

(d) the amino acid residue at the P2 position is proline, alanine, leucine, isoleucine, glycine, valine, or threonine; and

(e) the amino acid residue at the P1 position is alanine, leucine, valine, isoleucine, or serine.

3. The nucleic acid molecule of claim 1 , wherein the amino acid residue at the P5 position is histidine.

4. The nucleic acid molecule of claim 1 , wherein the amino acid residue at the P4 position is threonine.

5. The nucleic acid molecule of claim 1 , wherein the amino acid residue at the P3 position is asparagine.

6. The nucleic acid molecule of claim 1 , wherein the amino acid residue at the P2 position is proline.

7. The nucleic acid molecule of claim 1 , wherein the amino acid residue at the P1 position is alanine.

8. The nucleic acid molecule of claim 1 , wherein the amino acid residues at the P3-P1 positions have the amino acid sequence of SEQ ID NO:20.

9. The nucleic acid molecule of claim 1 , wherein the amino acid residues at the P10-P1 positions have the amino acid sequence of SEQ ID NO:73.

10. The nucleic acid molecule of claim 1 , wherein the amino acid residues at the P10-P3′ positions have the amino acid sequence of SEQ ID NO:55.

11. The nucleic acid molecule of claim 1 , wherein the protein comprises an amino acid sequence which is at least 95% identical to the reference amino acid sequence.

12. The nucleic acid molecule of claim 1 , wherein the protein comprises an amino acid sequence which is at least 99% identical to the reference amino acid sequence.

13. The nucleic acid molecule of claim 1 , wherein the protein comprises an amino acid sequence which is identical to the reference amino acid sequence.

14. The nucleic acid molecule of claim 1 , wherein the protein further comprises a signal sequence.

15. The nucleic acid molecule of claim 1 , which is isolated.

16. The nucleic acid molecule of claim 1 , wherein the autoactivating type I pancreatic proelastase protein produces a mature type I pancreatic elastase having elastase activity following autoactivation.

17. The nucleic acid molecule of claim 1 , wherein the autoactivating type I pancreatic proelastase protein comprises a cleavage site that is cleaved by a mature type I pancreatic elastase having elastase activity.

18. The nucleic acid molecule of claim 1 , wherein autoactivation of the type I pancreatic proelastase protein produces a mature type I pancreatic elastase having elastase activity.

19. The nucleic acid molecule of claim 1 , wherein the protein lacks a signal sequence.

20. A vector comprising the nucleic acid molecule of claim 1 .

21. A host cell genetically engineered to express the nucleic acid molecule of claim 1 .

22. A cell culture supernatant comprising the autoactivating type I pancreatic proelastase protein encoded by the nucleic acid molecule of claim 1 .

23. A method of producing an autoactivating type I pancreatic proelastase protein, comprising culturing the host cell of claim 21 under conditions in which the autoactivating type I pancreatic proelastase protein is produced.

24. The method of claim 23 , further comprising recovering the autoactivating type I pancreatic proelastase protein.

Assignments (3)
CHANGE OF NAME Recorded Nov 30, 2020
From: ARTARA THERAPEUTICS, INC.
To: PROTARA THERAPEUTICS, INC.
Reel/Frame 054553/0688 →
MERGER Recorded Nov 18, 2020
From: PROTEON THERAPEUTICS, INC.
To: ARTARA THERAPEUTICS, INC.
Reel/Frame 054476/0140 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2020
From: FRANANO, F. NICHOLAS; BLAND, KIMBERLY S.; WONG, MARCO D.; DING, BEE C.
To: PROTEON THERAPEUTICS, INC.
Reel/Frame 054381/0358 →